CO COHANCE
Cohance Lifesciences Q2 2026
COCOHANCE

Cohance Lifesciences Q2 FY26 results (Jul–Sep 2025) and concall

Healthcare · Concall AI · Call held 28 Oct 2025

Management summary

  • Cohance Lifesciences used its Q2 FY26 update call to announce a significant organizational restructuring following the resignation of its Managing Director.
  • The company is moving toward a vertical-led structure with three new business CEOs reporting to the Executive Chairman to accelerate its $1 billion revenue target for 2030.
  • While no financial results were disclosed due to a silent period, management highlighted strong momentum in the CDMO pipeline, including a key Phase 3 win from a Japanese client.

Source: Inve concall analysis and management guidance record.

What they filed

₹ Cr · quarterly
Line itemQ3 FY25Q4 FY25Q1 FY26Q2 FY26
Revenue676 840 549 556
EBITDA237 229 112 121
Net profit153 117 46 66
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Guidance & targets

Revenue

  • Total Revenue Vision Revenue · by 2030 · High confidence US$1 billion

Capacity

  • Oligonucleotide Unit Commissioning Capacity · Q4 FY26 · High confidence Commissioned

Source: Inve Guidance Tracker — management targets and direct quotes from the earnings call transcript.

Q&A highlights

2 direct
Leadership Churn and Transition Management Direct
There is no single dependency on Dr. Prasada on any specific client. All these relationships were already transferred as part of normal transition to the business CEOs.

Investors were concerned about client retention following the MD's exit; management clarified that the new vertical CEOs already own these relationships.

Asked by Chirag Dagli, DSP Asset Managers

Cultural Integration of Six Entities Direct
Somebody started saying we are a combination of six family-owned businesses that have now become part of who we are today... there is definitely a transition in culture.

Highlights the execution risk of merging multiple legacy cultures into a single corporate platform, which management acknowledges as an ongoing journey.

Asked by Karthikeyan, Suyash Advisors

Unlock risks & concerns, Q3 FY26 watchlist, and full call analysis

You’re reading a preview. Opening the full call uses 1 concall credit and unlocks:

  • 3 risks, concerns & management red flags
  • Watchlist triggers for Q3 FY26
  • +1 more guidance target & verbatim management quotes
  • +1 more analyst Q&A exchange & evasion checks
  • Full section-by-section call narrative

Sign in to use your monthly call allowance.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared and our regulatory disclaimer. · Share on WhatsApp · Scorecard image